Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
- PMID: 2775320
- DOI: 10.1002/anr.1780320909
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
Abstract
Six systems for defining and evaluating disease activity in patients with systemic lupus erythematosus (SLE) (the Ropes system, the National Institutes of Health [NIH] system, the New York Hospital for Special Surgery system, the British Isles Lupus Assessment Group [BILAG] scale, the University of Toronto SLE Disease Activity Index [SLE-DAI], and the Systemic Lupus Activity Measure [SLAM]) were tested on 25 SLE patients who were selected to represent a range of disease activity. The patients were evaluated independently by 2 physicians on 2 occasions approximately 1 month apart. Differences between patients demonstrated the largest source of variation in scores, accounting for 56-84% of the total variance, depending on the instrument. Differences between physicians (i.e., error) showed the next largest variation, 11-28% of the total variance, and differences between visits made up 5-16% of the total. The BILAG, SLE-DAI, and SLAM had the best inter-visit and inter-rater reliability. Convergent validity was shown by the strong correlations of scores among the different instruments (r = 0.81-0.97). All instruments correlated highly with the physicians' clinical impression of disease but less well with their evaluation of disease severity. The number of American Rheumatism Association criteria for SLE that were met by the patients correlated poorly with the physicians' global evaluation and with the scores of the instruments. The patients' self-reported disease activity scores correlated highly with the physicians' assessments of disease activity (r = 0.85-0.91), and the mean values from self-reports and from physicians' assessments were nearly equal. In contrast, severity scores correlated less well between self-reports and physician assessments (r = 0.49-0.69), and mean self-reported severity values were lower than the means from physicians. The BILAG, SLE-DAI, and SLAM systems appear to have better psychometric properties than the others for clinical research.
Similar articles
-
Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.J Rheumatol. 2000 Mar;27(3):664-70. J Rheumatol. 2000. PMID: 10743805
-
Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus.Lupus. 2001;10(6):405-9. doi: 10.1191/096120301678646146. Lupus. 2001. PMID: 11434575 Clinical Trial.
-
Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda.Rheumatol Int. 1991;11(3):133-6. doi: 10.1007/BF00304502. Rheumatol Int. 1991. PMID: 1754816
-
Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-85-95. Epub 2014 Oct 30. Clin Exp Rheumatol. 2014. PMID: 25365095 Review.
-
[Evaluation of the clinical activity of systemic lupus erythematosus].Ann Med Interne (Paris). 1990;141(3):261-4. Ann Med Interne (Paris). 1990. PMID: 2195948 Review. French.
Cited by
-
Use of biomarkers in the management of children with lupus.Curr Rheumatol Rep. 2013 Mar;15(3):312. doi: 10.1007/s11926-012-0312-0. Curr Rheumatol Rep. 2013. PMID: 23355230 Review.
-
Association between depression and vascular disease in systemic lupus erythematosus.J Rheumatol. 2012 Feb;39(2):262-8. doi: 10.3899/jrheum.110327. Epub 2011 Dec 15. J Rheumatol. 2012. PMID: 22174200 Free PMC article.
-
Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations.Clin Exp Immunol. 1990 Nov;82(2):268-74. doi: 10.1111/j.1365-2249.1990.tb05438.x. Clin Exp Immunol. 1990. PMID: 2242607 Free PMC article.
-
Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity.Clin Exp Immunol. 2000 Jan;119(1):189-95. doi: 10.1046/j.1365-2249.2000.01107.x. Clin Exp Immunol. 2000. PMID: 10606982 Free PMC article.
-
Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.Int J Rheum Dis. 2018 Aug;21(8):1609-1618. doi: 10.1111/1756-185X.13363. Int J Rheum Dis. 2018. PMID: 30146745 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous